Combination therapy for early Alzheimer's disease: What are we waiting for?

Journal of the American Geriatrics Society

Volumn 46, Issue 10, 1998, Pages 1322-1324

  Doraiswamy, P Murali ^a   Steffens, David C ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; ESTROGEN; GINKGO BILOBA EXTRACT; RETINOL; VASOACTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HUMAN; MENTAL FUNCTION; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0031686932     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1998.tb04556.x     Document Type: Article

References (24)

1. Giacobini E,. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997; 74: 225-241.
2. Doraiswamy PM,. Current cholinergic therapy for symptoms of Alzheimer's disease. Prim Psychiatry 1996; 3: 56-68.
3. Knopman DS, Morris JC,. An update on primary drug therapies for Alzheimer disease. Arch Neurol 1997; 54: 1406-1409.
4. Small GW, Rabins PV, Barry PP, et al,. Diagnosis and treatment of Alzheimer disease and related disorders. JAMA 1997; 278: 1363-1371.
5. Rogers SE, Farlow MR, Doody RS, et al,. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
6. Rogers SL, Friedhoff LT,. Long term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicenter open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
7. Knopman DS,. Metrifonate for Alzheimer's disease: Is the next Cholinesterase inhibitor better? Neurology 1998; 50: 1203-1205.
8. Thal LJ, Schwartz G, Sano M, et al,. A multicenter double-blind study of controlled-release physostigminc for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996; 47: 1389-1395.
9. Corey-Bloom, Arnand R, Veach J for the ENA713B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA713 (rivastigmine tar-trate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;(S1): 55-65.
10. Solomon PR, Knapp MJ, Gracon SI, et al,. Long-term tacrine treatment in patients with Alzheimer's disease. Lancet 1996; 348: 275-276.
11. Morris JC, Cyrus P, Orazem J, et al,. Metrifonate benefits cognitive, behavioral and global function in Alzheimer's disease. Neurology 1998; 50: 1222-1230.
12. Raskind M, Sadowsky C, Sigmund W, et al,. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Arch Neurol 1997; 54: 836-840.
13. Tang M-X, Jacobs D, Stern Y, et al,. Effect of estrogen during menopause on risk and age at onset of Alzheimer disease. Lancet 1996; 348: 429-432.
14. McGeer PL, Schulzer M, McGeer EG,. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies. Neurology 1996; 47: 425-432.
15. Pitchumoni S, Doraiswamy PM,. Current status of antioxidant therapy for Alzheimer's disease. J Am Geriatr Soc 1998, in press.
16. Sano M, Ernesto C, Klauber MR, et al,. A two-year, double-blind randomized multicenter trial of selegiline and alpha-tocopherol in the treatment of Alzheimer's disease. N Engl J Med 1997; 336: 1216-1222.
17. Tariot PN, Goldstein B, Podgorski CA, et al,. Short-term administration of seligiline for mild-to-moderate dementia of the Alzheimer's type. Am J Geriatr Psychiatry 1998; 6: 145-154.
18. LeBars PL, Katz MM, Berman M, et al,. A placebo-controlled double blind randomized trial of an extract of ginkgo biloba for dementia. JAMA 1997; 278: 1327-1332.
19. Rother H, Erkinjutti T, Roessner M, et al,. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of phase III trials. Dement Geriatr Cogn Disord 1998; 9 (Sl): 36-43.
20. Doraiswamy PM, Krishnan KR, Nemeroff CB,. Neuropeptides and neurotransmitters in Alzheimer's disease. Bailliere's Int Clin Endocrinol Metab 1991; 5: 159-77.
21. Sunderland T, Molchan S, Lawlor B, et al,. A strategy of combination therapy in Alzheimer's disease: Rationale and preliminary results with physostigmine plus deprenyl. Int Psychogeriatr 1992; 2: 291-309.
22. Doraiswamy PM, Steffens DS, Tabrizi S, Pitchumoni S,. Early recognition of Alzheimer's disease: What's consensual? What's controversial? What's practical? J Clin Psychiatry 1998; 59: 6-18.
23. Tariot PN, Schneider LS,. Treating Alzheimer's disease. Postgrad Med 1997; 101: 73-90.
24. Schneider L, Farlow M, Henderson V, Pogoda JM,. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996; 46: 1580-1584.